Trial Profile
A Single-Center Phase 1/2 Study of Single- or Fractioned-Dose Gemtuzumab Ozogamicin in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone for Previously Untreated Adult Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Cladribine (Primary) ; Cytarabine (Primary) ; Gemtuzumab ozogamicin (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Mitoxantrone (Primary)
- Indications Acute myeloid leukaemia; Neoplasms by histologic type
- Focus Adverse reactions; Therapeutic Use
- 10 Aug 2023 Status changed from active, no longer recruiting to completed.
- 14 Dec 2021 Results assessing safety and efficacy of combining gemtuzumab ozogamicin with dose-escalated mitoxantrone as initial therapy for fit adults with newly diagnosed acute myeloid leukemia or high-grade myeloid neoplasm, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
- 12 Jan 2021 Status changed from recruiting to active, no longer recruiting.